iCAD, Inc. (NASDAQ:ICAD) Q3 2023 Earnings Call Transcript

iCAD, Inc. (NASDAQ:ICAD) Q3 2023 Earnings Call Transcript November 13, 2023

Operator: Good day, everyone and welcome to the iCAD, Inc. Third Quarter 2023 Earnings Call. At this time, all participants have been placed in a listen-only mode and we will open the floor for your questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Leonor Faber. Ma’am, the floor is yours.

Leonor Faber: Thank you, operator. Good afternoon, everyone. Thank you for joining us today for iCAD’s third quarter 2023 earnings call. On the call today, we have Dana Brown, our President and Chief Executive Officer; and Eric Lonnqvist, our Chief Financial Officer. Before turning the call over to Dana, I would like to remind everyone that we will be making forward-looking statements on the call today. These forward-looking statements are based on iCAD’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations. For a list of factors that could cause actual results to differ, please see today’s press release and our filings with the U.S. Securities and Exchange Commission.

iCAD undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. I would also note that management will refer to certain non-GAAP financial measures. Management believes that these measures provide meaningful information for investors and reflect the way they view the operating performance of the company. You can find a reconciliation of our GAAP to non-GAAP measures at the end of the earnings release. With that, I’ll turn the call over to Dana.

Dana Brown: Thank you, Leonor and good afternoon, everyone. Let’s begin with our business update. On October 23, we announced that Elekta, a world leader in brachytherapy solutions acquired Xoft, our therapy subsidiary for approximately $5.5 million and assumed liabilities. As previously disclosed, we have been in the process of exploring strategic options for the Xoft business that would accelerate the accessibility of this technology and provide more focus and synergies to its growth. We’re pleased that Elekta has acquired the Xoft subsidiary, along with both the technology and the team. We’re confident that the Xoft technology under the leadership of John Lapre, will continue to positively impact the lives of cancer patients and the providers who care for them on a global scale.

Elekta took over the business effective immediately upon signing and have completed their final payments. Later in this call, Eric will provide further updates on the transaction and its impact on cash, our balance sheet and operations. Our thanks to the outstanding work of the Craig-Hallum Capital Group who served as advisers to us for this transaction. Let’s now turn to the detection side of the business. As we close out 6 months since our leadership transition and finalized our growth plans for 2024 and beyond, it’s important to recap the trajectory of changes we’ve made and how those changes are setting us up for future success. In just 6 months, we’ve made substantial progress executing a 3-phase transformation. Phase 1 was realigning our base; Phase 2, strengthening our foundation and Phase 3 investing in growth initiatives.

Let’s start with Phase 1, realigning our base. In the past 6 months, we have stabilized the business through reducing our cash burn. EBITDA which we now view as a relevant metric to indicate operating cash flow was a loss of $1.1 million in Q3 ’23 versus a loss of $3 million in Q1 of ’23. This represents an improvement of nearly $2 million a quarter. We’ve reduced our cash burn. Year-to-date, FY ’23 total cash burn of $4.4 million which excludes the onetime cash infusions like our projected Xoft proceeds compared to full year FY ’22 cash burn of $13 million. We believe cash burn has stabilized. We’ve continued to manage the shift to a subscription-based annual reoccurring revenue cycle. We’ll talk more about ARR growth later in this call. But in summary, we had a 30% increase in ARR since the start of the subscription transition.

We’ve achieved 16% compounded annual growth rate and total ARR over the 2-year period or through the end of Q3 ’23. And we’ve completed the realignment of our cost base for our core business and I’m pleased to affirm the company does not need to raise additional funding to pursue growth initiatives. In Phase 2, strengthening the foundation in the past 6 months, we have expanded our leadership team with the appointment of our permanent CFO, Eric and the addition of a COO, Chief Product Officer, Vice President of Marketing and Vice President of Customer Success. We’re also making good progress in recruiting new Board members. We’ve upgraded our brand by transitioning from a product-focused to a patient-centric value proposition, resulting in our new tagline of creating a world where cancer can’t hide, you’ll see more of the rebrand launch in Q4 and we’ve developed and launched targeted lead gen programs.

Previously, a reliable and consistent inflow of new leads and a documented and measured pipeline management process did not exist. We’ve revamped our commercial model, reorganized our team structure, how we target and segment our markets, revised messaging pricing and account management strategies. We’ve announced game-changing collaborations with esteemed partners, exemplifying our company’s commitment to creating the world’s most pervasive and personalized suite of AI cancer detection solutions for our shareholders and stakeholders. To recap these partnerships, we signed a 20-year worldwide development and commercialization agreement with Google Health to integrate Google’s AI technology with our profound detection for 2D mammography, for use upon regulatory approval as an independent reader for breast cancer screening.

We signed a strategic multiyear commercial agreement with Radiology Partners, the nation’s largest radiology practice, providing 15% of all U.S. mammography screening through its owned and affiliated practice, enabling iCAD to expand access to the company’s breast AI suite to thousands of physicians and millions of patients in the U.S. We’ve just wrapped up our testing phase and we’ll begin the next phase of identifying and coordinating rollout with radiology partners across its network of facilities. And we’ve secured the largest subscription deal to date with a prestigious multi-specialty academic medical center renowned for exceptional health care services and ranked as one of the top hospitals in the U.S. And last but not least, the divestiture of Xoft, coupled with realigning our cost basis and strengthening key foundational building blocks, we’ve completed the necessary steps to streamline operations and put all our focus into scaling the ProFound AI Breast Health business, immediately prioritizing, expanding our sales and partnership models to grow revenue which leads us to Phase 3, investing in and launching growth initiatives.

On the prior two earnings calls, I’ve noted we are actively assessing and modeling revenue growth and market expansion scenarios. We’ve aligned on a 3-phase approach. Phase 1, expanding our existing accounts, Phase 2, growing our channels, both direct and indirect and Phase 3 entering new markets; these phases will overlap. However, we’ve clearly defined dates and gates which are measurable criteria to act as triggers within a phase to open the gate into the next phase. We’ve orchestrated these phases to maximize growing annual recurring revenue while keeping burn in check which is why we believe we do not need to raise additional funding to pursue the growth initiatives in Phase 3. Let’s take a few moments and break these phases down. Phase 1 is Expand Existing Accounts.

This phase is focused on maximizing revenue from our sizable installed base, including reengaging customers who’ve lapsed on annual maintenance service agreements, are behind and upgrading to new versions, including the transition to cloud, winning back lost or deeply less customers and accelerating deployment across large national accounts. For example, I just mentioned our strategic multiyear commercial agreement with Radiology Partners. Radiology Partners is a leading provider of mammography services to millions of women across more than 3,200 facilities, including 17 of the 20 largest health systems in the country. We’re honored that Radiology Partners has selected iCAD as its provider of breast AI technologies and we’re working closely with Radiology Partners to actively deploy iCAD’s advanced technology through their cloud to their network of facilities.

The initial order from Radiology Partners recognized in on first quarter of this year represents less than 5% of the total potential from this partnership. It’s a long-term relationship and will take time to adopt and roll out across their large enterprise. And while you’ve heard us announce in past quarters, winning deals with large enterprise customers like Solis, Radiology Partners, SimonMed, Ascension and Cleveland Clinic, who collectively serve about 15% of the U.S. mammography screening market, great potential lies ahead for iCAD as many of these customers are in the early stages of rolling out our technology and are continuing to expand into more sites and markets each month. The focus of this phase is to accelerate deployment of our technology across these national and regional accounts as well as re-engage approximately 1,000 of our 4,000 customers who’ve lapsed on their maintenance agreements or who are operating on older software versions.

Moving to Phase 2 which is growing channels, both direct and indirect. This phase is focused on accelerating winning new business in both the U.S. and OUS through growing our direct sales force and establishing new distribution partnerships. Backed by science, the clinical evidence and proven patient outcomes, our ProFound Breast Health suite solutions of cancer detection, density assessment and risk evaluation, provide an unmatched approach to accurately detecting more cancers earlier, providing certainty and peace of mind to providers and patients. Our mission is to see that these solutions are deployed universally as part of a standard of care for breast health in order to achieve our vision of a world where cancer can’t hide. We’re pursuing a large addressable market where significant patient need exists.

Globally, more than 31,000 mammography systems serve approximately 250 million women in the age range recommended for annual mammograms. Yet recent research indicates only 37% of mammography sites are currently using artificial intelligence. In the United States, for example, there are 8,800 certified mammography sites. Of the 37% of sites using AI, we have 1/3 of that market. Expanding into the 63% of the market that is not using AI, plus additional wins in the segment using AI but not ProFound, results in significant opportunity for new business. We believe U.S. sales have declined due in part to a significant reduction in the sales force that occurred in FY ’22. In the U.S., we currently have 6 sales reps versus 12 in Q3 of FY ’22. After a thorough analysis of rep performance over the past 3 years, we believe adding additional sales reps focused on new business given our large addressable market opportunity I just discussed and reps focused on large national accounts like Radiology Partners will lead to revenue growth which leads us to Phase 3 entering new markets.

After measurable progress in Phases I and II, will begin Phase 3, most likely in FY ’25. As mentioned on prior earnings calls and as just one example of growth is our work with Solis mammography to commercialize our heart health solution which was previously referred to as breast arterial classification. In fourth quarter 2022, we announced the development and commercial collaboration agreement with Solis. This collaboration is focused on using mammography to define cardiovascular risk, a new application that could identify millions of women at risk for heart disease using data obtained from their mammogram. With heart disease being the number one killer among women in the U.S., this collaboration not only offers the potential to address a significant unmet need in patient care but also to penetrate a sizable new market.

A medical professional in a hospital room with modern medical devices in the background.

This product is currently available for investigational use only as we go through the FDA approval process, so more to come. Just to reiterate, once we’ve reached critical mass in Phases 1 and 2, that warrant and enable us to expand our focus, we’ll update you on our growth initiatives. Let’s now turn to a few brief Q3 highlights. Our sales force continues to secure opportunities with some of the most esteemed and prestigious health care facilities worldwide. Among the new licenses sold last quarter, we also secured our first 2 customers through our AI platform partner, Ferrum Health, Sutter Health and Radiology Associates that offer therapy. Ferrum Health is a leading AI platform provider, delivering access to the most innovative and impactful clinical AI technologies on a single platform.

We expect additional expansion with Ferrum in Q4 and beyond with significant near-term expansion opportunities within the Sutter Health System which encompasses more than 20 sites. We also expanded deployment with our key partner, Solis Mammography, adding 2 new Solis sites in Texas. We expect continued expansion with Solis across new U.S. markets in Q4 and beyond as the Solis model of personalized care continues to expand nationally. Solis Mammography has approximately 115 sites nationwide. And to date, we’ve implemented our solution at 85% of those sites. We also continued expansion within the government sector, adding the prestigious Walter Reed National Naval Medical Center and the VA Medical Center in Birmingham, Alabama. Reinforcing the strategy and near-term revenue opportunities in Phase 1, expanding into existing accounts, you’ve heard us announce in past quarters winning deals with large enterprise customers like Solis, Radiology Partners, SimonMed, Ascension and Cleveland Clinic, who collectively serve about 15% of the U.S. mammography screening market.

Great potential lies ahead for iCAD as many of these customers are in the early stages of rolling out the technology and are continuing to expand into more sites and markets each month. During the past quarter, we also achieved several key milestones with our OUS sales channel, further expanding the growing global reach of iCAD’s technology. Our direct sales force in France achieved a ground-breaking milestone by finalizing its most significant deal to date, 13 ProFound AI licenses were sold to a leading radiology group in Dijon, France. Our OUS team also signed and onboarded 2 new distributors to oversee operations in the United Arab Emirates and Slovenia, Croatia. Our BeNeLux distributors not only secured a pivotal deal with Brussels University in Belgium but also expanded their support to the Luxembourg screening program by adding 8 density assessment licenses alongside the existing detection licenses sold in Q2.

And several first marked Q3 with the Saudi Arabian distributors completing their first customer sale for ProFound AI 2D, 3D and the first customer site installs occurring in Turkey. And lastly, a preview of our showcase at RSNA 2023 occurring November 25 through 30. At RSNA, iCAD will be demonstrating new AI-powered innovations in mammography, highlighting new product enhancements, partnerships and workflow solutions featuring our ProFound Breast Health suite. We’re featured in 4 clinical abstracts, including presentations from both Dr. Axel Gräwingholt of Radiologie am Theater, Paderborn Germany; and Dr. Mikael Eriksson of the Karolinska Institute on new data highlighting profound risks, short-term risk assessment capabilities for evaluating development of breast cancer in the next 1 to 2 years, including a multinational validation of a clinical image-based AI risk model for individualizing breast cancer screening.

Presentations from both Dr. Sharad Patel of Solis Mammography and Dr. Thu Ha Dao of Henri-Mondor Hospital on the novel application of deep learning AI to detect and quantify breast arterial calcification on digital mammography. As I mentioned earlier, this solution has not yet been cleared by the FDA for commercial use. It’s being used in investigational mode only at this time and expect clearance in late 2024. And Emily Conant, Professor of Radiology and the Vice Chair of Faculty Development in the Department of Radiology at the University of Pennsylvania, Perelman School of Medicine and past President of SDI, will be highlighting new data from iCAD’s fourth generation enhancements during the AI showcase theater presentation titled: From Pixels to Practice, Harnessing Innovations in Breast AI to Improve Patient Outcomes.

We will also be demonstrating new product enhancements, including our new ProFound Detection Version 4.0 and density version 4.1 solutions that streamline workflows, provide support for analysis of prior mammograms, identify cancers even earlier with more accuracy and lead to improved patient outcomes. I continue to be optimistic about the company and its prospects. With a portfolio of market-leading first-in-time technologies, we are addressing significant unmet needs in global health. And I’m confident that we are taking the right steps and that we’re building the right team to ensure continued growth for the company and create additional shareholder value. In summary, we’re taking decisive actions to drive rapid transformation within the company, prioritizing stability, cash preservation and the development of a strong competitive long-term strategy.

Our goal is to diversify our revenue stream and reduce customer concentration, ensuring a more sustainable and resilient future. I’ll now turn the call over to Eric for a detailed review of our Q3 2023 financials.

Eric Lonnqvist: Good afternoon, everyone and thank you, Dana. I’ll now summarize our financial results for the third quarter ended September 30, 2023. Please note that these results exclude the divested Xoft segment. Results relating to the Xoft segment are presented in Note 2 of our 10-Q. Revenue for the quarter was $4.1 million, a decline of $0.3 million or 7% from the third quarter of 2022. Third quarter 2023 product revenue was $2.2 million, down 15% over the prior year. The decline is attributable to a variety of factors, including our transition to subscription, longer purchasing cycles, increased competition and budget constraints. Detection service revenue was $1.9 million, up 3% over the prior year. Moving on to gross profit.

On a percentage of revenue basis, gross profit was 86% for the third quarter of 2023 which was up from 85% in the third quarter of 2022. On a pure dollar basis, gross profit for the quarter was $3.5 million as compared to $3.7 million last year, largely reflective of the reduction in revenues. Total operating expenses for the second quarter of 2023 were $4.7 million, $2 million or a 29% decrease year-over-year. This improved run rate reflects the implemented cost-cutting measures previously announced. Operating loss was $1.2 million in the second quarter of September 30, 2023, versus $3 million in quarter ended September 30, 2022. The GAAP net loss for the third quarter of 2023 was $1.4 million or $0.05 per diluted share compared with a GAAP net loss of $3.9 million or $0.15 per diluted share for the third quarter of 2022.

Non-GAAP adjusted EBITDA for the third quarter of 2023 was a loss of $1.1 million versus $3.4 million in Q3 2022. Non-GAAP adjusted net loss for the quarter was $1.4 million or $0.05 per diluted share compared to $3.9 million or $0.15 per diluted share in Q3 2022, reflecting a few adjustments to GAAP net loss in each period. Moving on to the balance sheet. As of September 30, 2023, the company had cash and cash equivalents of $19 million compared to cash and cash equivalents of $21.3 million on December 31, 2022. During the third quarter, the company generated net proceeds of approximately $1.8 million from the issuance of 958,248 shares of common stock in the aftermarket ATM offerings at a weighted average price of $2.26 per share. In addition, the Xoft sale in October 2023 resulted in net cash proceeds of $4.8 million.

Had the sale of Xoft occurred on September 30, 2023, our cash balance would have been $23.8 million. Accordingly, we believe we have sufficient cash resources to fund our planned operations with no need to raise additional funding. The steady shift to a recurring revenue model from the perpetual model has numerous benefits, including better visibility, more efficient expense management and an improved ability to predict future cash flow. It also has risks, including short-term lower GAAP revenue and negative cash flow impact for the next 3 years. As noted in previous earnings announcement, our plan was to bring back the annual recurring revenue, ARR metric once they have become a reliable and growing portion of our revenue mix. In addition to the previously disclosed subscription ARR metric, we are introducing 3 new ARR metrics.

Total ARR or TARR, represents the annualized value of subscription license maintenance contracts and active cloud services at the end of a reporting period. Maintenance Services ARR or MARR represents the annualized value of active perpetual license maintenance service contracts at the end of the reporting period. Subscription ARR or SARR, represents the annualized value of active subscription or term licenses at the end of a reporting period. Cloud ARR, or CARR represents the annualized value of active cloud services contracts at the end of the reporting period. As of the end of Q3 ’23, Total ARR or TARR was $8.3 million. Maintenance Services ARR or MARR was $6.9 million. Subscription ARR or SARR, was $1.4 million. Once we have released our commercial cloud platform, we’ll begin tracking cloud ARR.

In addition to the recurring revenue metrics noted above, we will begin to disclose the total number of orders relating to perpetual product, subscription and cloud deals. The intent of this metric is to illustrate the pure volume of sales without the complexity of multiple GAAP revenue streams. We are pleased to report that in Q3 ’23, we closed 60 perpetual and 7 subscription orders. This brings our year-to-date total to 193 perpetual and 62 subscription orders. This concludes the financial highlights of our presentation. I would now like to turn the call back over to the operator to lead the Q&A.

See also 15 Internet Retail Stocks To Buy and Bill Gates’ Portfolio of Stocks.

Q&A Session

Operator: Certainly. Everyone at this time, we’ll be conducting a question-and-answer session. [Operator Instructions] Your first question is coming from Per Ostlund from Craig-Hallum Capital.

Per Ostlund: Good afternoon Dana and Eric. Congratulations, first and foremost, on the Xoft divestiture. It’s nice to see the resolution there after the process really didn’t start that long ago. So congrats on that. A lot of places we could go here, I think. Obviously, looking at the release and seeing that the Xoft business is now in the discontinued operations, I think it does really highlight the margin profile of the standalone detection business. So maybe just a couple of questions around that to start out with, if I could. The expense structure looks like it came down by about 1/3 year-over-year, the operating expense structure. You’ve done an admirable job there and then spoken at some length about that over the last couple of quarters. Is there more to go there on that front? And sort of part and parcel with that, do you have a breakeven revenue level in mind for the stand-alone AI business, whether it’s on an EBITDA basis or a cash flow basis.

Dana Brown: Thanks, Per. So I’m going to turn the questions over to Eric but just wanted to say thanks and thanks for the comments on Xoft. Just maybe one data point there. We were thrilled that elected to both the technology and the team. There was great market potential, I think, for the Xoft technology is just really difficult to do with 2 very different lines of business kind of under the same umbrella. So pleased that you’re already kind of zeroing in on what the detection business looks like stand-alone. So because that’s what we’ve been focused on and trying to get to on these calls. So with that, I’m going to turn it over to Eric, so we can talk about kind of expense structures and where our thoughts are.

Eric Lonnqvist: Hi. Thanks, Dana. Yes, I think on the Xoft, we… With the furloughs and then all the other things we did in the last 3 quarters, I don’t think there’s going to be as much savings next quarter as you might expect. If you’re just looking at what we lost in the past historically for Xoft and thinking it’s going to come down significantly. We pulled back on clinical spend and employee spend significantly. So there could be some. And we did release in our 10-K, the direct Xoft impact. So there was about a $377,000 loss in Q3. So that’s called out. So that’s what we lost from direct Xoft business. So might pick some of that up going forward. I don’t think it will be much more than that.

Per Ostlund: Okay. So I guess maybe on that point since one of the discussion points in the prepared remarks is growth initiatives. So if we look at the third quarter expense structure for — again, for Detection stand-alone, how much might actually need to come back now that you’ve got the Xoft proceeds and that transaction is completed and you’ve raised the funds through the at-the-market facility, you feel good about your cash position. Is there a spend that might need to come back now that you have that singular focus on AI, whether it is sort of redeveloping the sales force you commented, how the direct force is maybe down 50% year-over-year in terms of people — is that something that gets bolstered what else might get bolstered now that you feel like you’re level set around one initiative.